 Avalon GloboCare Corp NASDAQ:AVCO said its planned acquisition target, SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor CAR T-cell therapy for recurrent glioblastoma. Glioblastoma is the most common type of primary brain tumor -- a devastating and aggressive cancer with few treatment options. 